Gene expression changes in early phase of venom immunotherapy - GSE92866

Genome-wide gene expression profiles of patients with severe hymenoptera venom allergy (HVA) were conducted to better understand the better the molecular processes underlying the acquisition of immune-tolerance during VIT (venom immunotherapy).

Study includes 11 HVA patients sampled prior VIT; 12 HVA patients sampled after 12months of VIT; 12 patients sampled between 1st and 2nd month of VIT; 12 individuals with negative skin tests for HVA; 12 beekeepers.

Venom immunotherapy

12 individuals with negative skin test

All patients undergone ultra-rush venom immunotherapy (VIT-UR) protocol. VIT-UR begins with the initial venom dose of 0.1 mcg and the summary dose of 111.1 mcg is reached within 3.5 hours. Maintenance dose of 100 mcg venom was administered every 4 weeks. Standardized lyophilized venom allergen extract (Pharmalgen Alk Abello) was used for build-up phase of VIT, and aluminum hydroxide adsorbed insect venom (Alutard-Alk Abello) for maintenance phase of therapy